Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent

BACKGROUND: Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line treatment. The presence of monoclonal gammopathy (MG) is a known adverse progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondello, Patrizia, Pitini, Vincenzo, Barresi, Valeria, Brea, Elliott Joseph, Di Mirto, Cristian, Arrigo, Carmela, Cuzzocrea, Salvatore, Mian, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702294/
https://www.ncbi.nlm.nih.gov/pubmed/26740908
http://dx.doi.org/10.1186/s40164-015-0030-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702294/
https://www.ncbi.nlm.nih.gov/pubmed/26740908
http://dx.doi.org/10.1186/s40164-015-0030-1

Ejemplares similares